Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets

Hepatitis B infections have become a serious public health issue globally, and the current first-line antiviral treatment for this disease is not a true cure. Recently, sodium taurocholate cotransporting polypeptide (NTCP), a liver-specific bile acid transporter, was identified as a bona fide recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yueran, Li, Shangda, Liang, Weifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062556/
https://www.ncbi.nlm.nih.gov/pubmed/30050063
http://dx.doi.org/10.1038/s41426-018-0137-7
_version_ 1783342393855049728
author Yu, Yueran
Li, Shangda
Liang, Weifeng
author_facet Yu, Yueran
Li, Shangda
Liang, Weifeng
author_sort Yu, Yueran
collection PubMed
description Hepatitis B infections have become a serious public health issue globally, and the current first-line antiviral treatment for this disease is not a true cure. Recently, sodium taurocholate cotransporting polypeptide (NTCP), a liver-specific bile acid transporter, was identified as a bona fide receptor for hepatitis B virus (HBV) and its satellite virus, hepatitis delta virus (HDV). Identification of the HBV receptor has led to the development of robust cell cultures and provides a potential target for new treatments. This review summarizes the process by which NTCP was discovered and describes its clinical significance as the receptor for HBV and HDV entry.
format Online
Article
Text
id pubmed-6062556
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-60625562018-07-27 Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets Yu, Yueran Li, Shangda Liang, Weifeng Emerg Microbes Infect Review Article Hepatitis B infections have become a serious public health issue globally, and the current first-line antiviral treatment for this disease is not a true cure. Recently, sodium taurocholate cotransporting polypeptide (NTCP), a liver-specific bile acid transporter, was identified as a bona fide receptor for hepatitis B virus (HBV) and its satellite virus, hepatitis delta virus (HDV). Identification of the HBV receptor has led to the development of robust cell cultures and provides a potential target for new treatments. This review summarizes the process by which NTCP was discovered and describes its clinical significance as the receptor for HBV and HDV entry. Nature Publishing Group UK 2018-07-26 /pmc/articles/PMC6062556/ /pubmed/30050063 http://dx.doi.org/10.1038/s41426-018-0137-7 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Yu, Yueran
Li, Shangda
Liang, Weifeng
Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets
title Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets
title_full Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets
title_fullStr Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets
title_full_unstemmed Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets
title_short Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets
title_sort bona fide receptor for hepatitis b and d viral infections: mechanism, research models and molecular drug targets
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062556/
https://www.ncbi.nlm.nih.gov/pubmed/30050063
http://dx.doi.org/10.1038/s41426-018-0137-7
work_keys_str_mv AT yuyueran bonafidereceptorforhepatitisbanddviralinfectionsmechanismresearchmodelsandmoleculardrugtargets
AT lishangda bonafidereceptorforhepatitisbanddviralinfectionsmechanismresearchmodelsandmoleculardrugtargets
AT liangweifeng bonafidereceptorforhepatitisbanddviralinfectionsmechanismresearchmodelsandmoleculardrugtargets

Ejemplares similares